A genetic variant in ERCC2 is associated with gastric cancer prognosis in a Chinese population

Mutagenesis

Volumn 28, Issue 4, 2013, Pages 441-446

  Chu, Haiyan ^a   Gu, Dongying ^b   Xu, Ming ^a   Xu, Zhi ^b   Gong, Yonglin ^b   Gong, Weida ^c   Tang, Yongfei ^d   Zhou, Jianwei ^a   Tong, Na ^a   Zhang, Zhengdong ^a   Chen, Jinfei ^a,b   Wang, Meilin ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c Yixing Cancer Hospital   (China)

^d YIXING PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GENOMIC DNA; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHINESE; CLINICAL FEATURE; DISTANT METASTASIS; FEMALE; FOLLOW UP; GASTRECTOMY; GENETIC ASSOCIATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POPULATION GENETICS; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; SURVIVAL TIME; TUMOR INVASION;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; STOMACH NEOPLASMS; TUMOR BURDEN; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 84881650772     PISSN: 02678357     EISSN: 14643804     Source Type: Journal    
DOI: 10.1093/mutage/get023     Document Type: Article

References (35)

1. Jemal, A., Siegel, R., Xu, J. and Ward, E. (2010) Cancer statistics, 2010. CA. Cancer J. Clin., 60, 277-300.
2. Parkin, D. M., Bray, F., Ferlay, J. and Pisani, P. (2005) Global cancer statistics, 2002. CA. Cancer J. Clin., 55, 74-108.
3. Theuer, C. P. (2000) Asian gastric cancer patients at a southern California comprehensive cancer center are diagnosed with less advanced disease and have superior stage-stratified survival. Am. Surg., 66, 821-826.
4. Schwarz, R. E. and Zagala-Nevarez, K. (2002) Ethnic survival differences after gastrectomy for gastric cancer are better explained by factors specific for disease location and individual patient comorbidity. Eur. J. Surg. Oncol., 28, 214-219.
5. Seevaratnam, R., Bocicariu, A., Cardoso, R., Yohanathan, L., Dixon, M., Law, C., Helyer, L. and Coburn, N. G. (2012) How many lymph nodes should be assessed in patients with gastric cancer? A systematic review. Gastric Cancer, 15 (Suppl. 1), S70-S88.
6. Hartgrink, H. H., Jansen, E. P., van Grieken, N. C. and van de Velde, C. J. (2009) Gastric cancer. Lancet, 374, 477-490.
7. Reed, E. (2005) ERCC1 and clinical resistance to platinum-based therapy. Clin. Cancer Res., 11, 6100-6102.
8. Sargent, R. G., Meservy, J. L., Perkins, B. D., Kilburn, A. E., Intody, Z., Adair, G. M., Nairn, R. S. and Wilson, J. H. (2000) Role of the nucleotide excision repair gene ERCC1 in formation of recombination-dependent rearrangements in mammalian cells. Nucleic Acids Res., 28, 3771-3778.
9. Handra-Luca, A., Hernandez, J., Mountzios, G., Taranchon, E., Lacau-St-Guily, J., Soria, J. C. and Fouret, P. (2007) Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin. Cancer Res., 13, 3855-3859.
10. Ozcan M. F., Dizdar, O., Dincer, N., et al. (2012) Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy. Urol. Oncol., doi:10.1016/j.urolonc. 2012.06.014.
11. Sung, P., Bailly, V., Weber, C., Thompson, L. H., Prakash, L. and Prakash, S. (1993) Human xeroderma pigmentosum group D gene encodes a DNA helicase. Nature, 365, 852-855.
12. Parshad, R., Tarone, R. E., Price, F. M. and Sanford, K. K. (1993) Cytogenetic evidence for differences in DNA incision activity in xeroderma pigmentosum group A, C and D cells after X-irradiation during G2 phase. Mutat. Res., 294, 149-155.
13. Lunn, R. M., Helzlsouer, K. J., Parshad, R., Umbach, D. M., Harris, E. L., Sanford, K. K. and Bell, D. A. (2000) XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis, 21, 551-555.
14. Yu, J. J., Lee, K. B., Mu, C., Li, Q., Abernathy, T. V., Bostick-Bruton, F. and Reed, E. (2000) Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int. J. Oncol., 16, 555-560.
15. Hao, T., Feng, W., Zhang, J., Sun, Y. J. and Wang, G. (2012) Association of four ERCC1 and ERCC2 SNPs with survival of bone tumour patients. Asian Pac. J. Cancer Prev., 13, 3821-3824.
16. Broughton, B. C., Steingrimsdottir, H. and Lehmann, A. R. (1996) Five polymorphisms in the coding sequence of the xeroderma pigmentosum group D gene. Mutat. Res., 362, 209-211.
17. Spitz, M. R., Wu, X., Wang, Y., et al. (2001) Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res., 61, 1354-1357.
18. Seker, H., Butkiewicz, D., Bowman, E. D., Rusin, M., Hedayati, M., Grossman, L. and Harris, C. C. (2001) Functional significance of XPD polymorphic variants: attenuated apoptosis in human lymphoblastoid cells with the XPD 312 Asp/Asp genotype. Cancer Res., 61, 7430-7434.
19. Giovannetti, E., Pacetti, P., Reni, M., et al. (2011) Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics, 12, 1641-1652.
20. Mahimkar, M. B., Samant, T. A., Kannan, S., Tulsulkar, J., Pai, P. S. and Anantharaman, D. (2012) Polymorphisms in GSTM1 and XPD genes predict clinical outcome in advanced oral cancer patients treated with postoperative radiotherapy. Mol. Carcinog., 51 (Suppl. 1), E94-103.
21. Zárate, R. N., Arias, F., Bandres, E., Cubedo, E., Malumbres, R. and García-Foncillas, J. (2006) Xeroderma pigmentosum group D 751 polymorphism as a predictive factor in resected gastric cancer treated with chemo-radiotherapy. World J. Gastroenterol., 12, 6032-6036.
22. Yin, M., Yan, J., Martinez-Balibrea, E., et al. (2011) ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin. Cancer Res., 17, 1632-1640.
23. Wang, M., Bai, J., Tan, Y., et al. (2011) Genetic variant in PSCA predicts survival of diffuse-type gastric cancer in a Chinese population. Int. J. Cancer, 129, 1207-1213.
24. Xu, Z., Zhu, H., Luk, J. M., et al. (2012) Clinical significance of SOD2 and GSTP1 gene polymorphisms in Chinese patients with gastric cancer. Cancer, 118, 5489-5496.
25. Lauren, P. (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol. Microbiol. Scand., 64, 31-49.
26. Xiao, H. W., Lai, X. Y., Luo, Y., et al. (2011) Relationship between TNFA, TNFB and TNFRII gene polymorphisms and outcome after unrelated hematopoietic cell transplantation in a Chinese population. Bone Marrow Transplant., 46, 400-407.
27. Kuper, J. and Kisker, C. (2012) Damage recognition in nucleotide excision DNA repair. Curr. Opin. Struct. Biol., 22, 88-93.
28. Gillet, L. C. and Schärer, O. D. (2006) Molecular mechanisms of mammalian global genome nucleotide excision repair. Chem. Rev., 106, 253-276.
29. Sancar, A. (1994) Mechanisms of DNA excision repair. Science, 266, 1954-1956.
30. Zhang, Z. Y., Tian, X., Wu, R., Liang, Y. and Jin, X. Y. (2012) Predictive role of ERCC1 and XPD genetic polymorphisms in survival of Chinese non-small cell lung cancer patients receiving chemotherapy. Asian Pac. J. Cancer Prev., 13, 2583-2586.
31. Isla, D., Sarries, C., Rosell, R., et al. (2004) Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol., 15, 1194-1203.
32. Wang, Z., Chen, J. Q., Liu, J. L., Qin, X. G. and Huang, Y. (2012) Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review. BMC Gastroenterol., 12, 137.
33. Xue, H., Lu, Y., Lin, B., Chen, J., Tang, F. and Huang, G. (2012) The effect of XPD/ERCC2 polymorphisms on gastric cancer risk among different ethnicities: a systematic review and meta-analysis. PLoS One, 7, e43431.
34. Hou, S. M., Fält, S., Angelini, S., Yang, K., Nyberg, F., Lambert, B. and Hemminki, K. (2002) The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk. Carcinogenesis, 23, 599-603.
35. Luo, D., Gao, Y., Wang, S., et al. (2011) Genetic variation in PLCE1 is associated with gastric cancer survival in a Chinese population. J. Gastroenterol., 46, 1260-1266.